-
公开(公告)号：EP4397679A1
公开(公告)日：2024-07-10
申请号：EP24150099.0
申请日：2024-01-02
IPC分类号： C07K14/71 , C07K14/495 , A61K38/17
CPC分类号： C07K14/71 , C07K14/495 , C07K2319/3020130101 , A61K38/179
摘要： This disclosure relates to engineered TGFβRII variants, protein constructs, and methods of use thereof.
-
公开(公告)号：EP4393941A1
公开(公告)日：2024-07-03
申请号：EP22860469.0
申请日：2022-08-23
发明人： YAN, Jiangyu , CAO, Rongbo , XIAO, Lin , ZENG, Junnan , HUANG, Limei , WEI, Xiling , LI, Zhaofeng , GONG, Qingwei , YAN, Xingguo , LI, Jing , HUANG, Danxia , CHEN, Xiaofeng , LI, Wenjia
CPC分类号： A61K38/18 , A61P3/00 , C07K14/475 , C07K16/46 , A61P3/08 , A61P3/06 , A61P3/04 , C07K2319/3020130101 , C07K2317/5220130101 , C07K2317/9420130101
摘要： The present invention relates to GDF15 fusion proteins and uses thereof. The fusion protein comprises an Fc variant and a GDF15 active domain, wherein the Fc variant has amino acid substitutions at position 356 and/or position 439 of the IgG Fc according to EU numbering and still has the ability to form homodimer. In the present invention, by fusing the Fc variant with the GDF15 active domain, the Fc-GDF15 fusion protein has significantly improved physicochemical properties and recombinant expression levels, has in vitro activity equivalent to or better than natural GDF15 molecules, and has significantly prolonged in vivo circulating half-life, which can support the dosing frequency of once every two weeks or even once a month.
-
公开(公告)号：EP4359075A2
公开(公告)日：2024-05-01
申请号：EP22829163.9
申请日：2022-06-21
IPC分类号： A61P7/06 , A61K35/18 , A61K35/19 , C07K14/495 , C07K14/71
CPC分类号： A61K47/68 , C07K16/22 , A61K2039/50520130101 , A61K2039/54520130101 , A61K2039/5420130101 , A61K38/1796
-
公开(公告)号：EP4269429A1
公开(公告)日：2023-11-01
申请号：EP21911559.9
申请日：2021-12-22
发明人： JANG, Mi-Hue , YUK, Chae-Min , GO, Ga-Yeon , LEE, Young-Eun , SHIN, Sang-Chul
IPC分类号： C07K14/495 , C07K7/08 , C07K7/06 , A61K38/00 , A61P35/00
摘要： The present invention relates to a novel peptide capable of inhibiting TGF-β signaling and the use thereof. The peptide of the present invention is capable of inhibiting the TGF-β-induced signaling pathway or the expression of TGF-β, and thus can treat or prevent various diseases caused by TGF-β signaling, and furthermore, can effectively inhibit tumorigenesis processes such as TGF-β-signaling induced tumor growth and metastasis.
-
5.发明公开
公开(公告)号：EP4225769A1
公开(公告)日：2023-08-16
申请号：EP21786507.0
申请日：2021-10-12
IPC分类号： C07K1/34 , C07K1/36 , C07K14/495 , C07K14/79
-
公开(公告)号：EP4149962A1
公开(公告)日：2023-03-22
申请号：EP21803999.8
申请日：2021-05-11
发明人： FREEMAN, Brian , BOSS, Olivier, D.
IPC分类号： C07K14/495 , A61K48/00 , C07K14/51
-
公开(公告)号：EP4144764A1
公开(公告)日：2023-03-08
申请号：EP21796635.7
申请日：2021-04-26
申请人： Sinocelltech Ltd.
发明人： XIE, Liangzhi , SUN, Chunyun , GUO, Erhong
IPC分类号： C07K19/00 , C07K14/71 , C07K14/495 , A61K38/17 , A61P35/00
摘要： Provided are multiple types of TGFβR2 in truncated forms and a fusion protein constructed by TGFβR2 and EGFR antibody HPA8; also provided are a nucleic acid (comprising heavy/light chain variable regions) encoding the antibody, a vector, a pharmaceutical composition, and a kit comprising the nucleic acid; further provided is a fusion protein of the prepared truncated TGFβR2 receptor protein and a targeted EGFR and other multiple types of tumor target antibodies.
-
-
公开(公告)号：EP3334750B1
公开(公告)日：2022-10-05
申请号：EP16834367.1
申请日：2016-08-11
发明人： Philip, Anie
IPC分类号： A01K67/027 , A61L31/16 , A61L15/44 , A61L17/00 , A61L24/00 , A61K35/36 , C07K14/495 , C07K14/705 , C07K14/71
-
公开(公告)号：EP3568142B1
公开(公告)日：2022-03-16
申请号：EP18702417.9
申请日：2018-01-12
-
-
-
-
-
-
-
-
-
搜索结果
451 条记录 (耗时 0.018 秒)
